Provided by Tiger Fintech (Singapore) Pte. Ltd.

SpringWorks Therapeutics, Inc.

46.99
0.0000
Volume:- -
Turnover:- -
Market Cap:3.54B
PE:-13.77
High:46.99
Open:46.99
Low:46.99
Close:46.99
Loading ...

SpringWorks Says EC Conditionally Approved EZMEKLY In Adults, Children

Reuters
·
19 Jul

Merck European Commission Grants Conditional Approval Of Ezmekly

Reuters
·
18 Jul

SpringWorks Therapeutics Inc. Finalizes Merger, Offering $47 Per Share to Stockholders

Reuters
·
01 Jul

Corrected-Merck KGaA (Not SpringWorks Therapeutics Inc) - Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of Its Healthcare Business (Corrects Source)

THOMSON REUTERS
·
01 Jul

BRIEF-Springworks Therapeutics Inc - Merck KGaA, Darmstadt, Germany Completes Acquisition Of Springworks Therapeutics To Accelerate Sustainable Growth Of Its Healthcare Business

Reuters
·
01 Jul

SpringWorks Therapeutics Inc - Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of Its Healthcare Business

THOMSON REUTERS
·
01 Jul

SpringWorks Therapeutics Inc. Conducted Special Stockholder Meeting

Reuters
·
27 Jun

BRIEF-Springworks Therapeutics Expects Nirogacestat Decision From European Commission In Q3

Reuters
·
20 Jun

SpringWorks Therapeutics: Nirogacestat Decision From European Commission Expected in Q3

THOMSON REUTERS
·
20 Jun

SpringWorks Therapeutics Awaits European Commission Decision on Approval of Nirogacestat for Desmoid Tumors, Expected Q3 2025

Reuters
·
20 Jun

BRIEF-EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment

Reuters
·
20 Jun

Ema's Chmp: Recommended Granting Conditional Marketing Authorisation for Rezdiffra, for Treatment of Adults With Noncirrhotic Mash

THOMSON REUTERS
·
20 Jun

Ema's Chmp: Positive Opinion Was Adopted for Ogsiveo, for the Treatment of Adults With Progressing Desmoid Tumours

THOMSON REUTERS
·
20 Jun

SpringWorks Therapeutics Announces Approval of Merger Agreement with Merck KGaA, Expects Completion in Second Half of 2025

Reuters
·
16 Jun

SpringWorks Therapeutics Inc. Announces Date for Special Stockholders Meeting

Reuters
·
28 May

Barclays Remains a Hold on Springworks Therapeutics (SWTX)

TIPRANKS
·
27 May

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN

Reuters
·
23 May

Springworks Therapeutics Says Mirdametinib Recommended by EU Panel for Treating Plexiform Neurofibromas

MT Newswires Live
·
23 May

BRIEF-SpringWorks Therapeutics Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN

Reuters
·
23 May

SpringWorks Therapeutics Inc - European Commission Decision on Mirdametinib Expected Q3 2025

THOMSON REUTERS
·
23 May